GlassScriptPhysician profile
Brock C Hansen
NPI 1992123376
$3,605.84
in general payments reported to CMS, 2019-2025
25 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.56 · 2020: $233 · 2021: $454 · 2022: $302 · 2023: $882 · 2024: $661 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.15 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $781.70 | 2020-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Idosetr |
| Alcon Vision LLC | $579.30 | 2021-2025 | Clareon, Centurion, Clareon Panoptix Pro |
| Abbvie INC. | $452.07 | 2022-2025 | |
| Biotissue Holdings INC. | $358.56 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $216.12 | 2020-2025 | Amo Phaco Needle, Veritas Vision System |
| Novartis Pharmaceuticals Corporation | $168.63 | 2019-2023 | |
| Rxsight INC | $158.61 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $155.91 | 2020-2025 | Cequa |
| Allergan, INC. | $131.87 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $116.38 | 2023-2025 | Stellaris, Stellaris, Envista Mx60 Iol |
| Sight Sciences, INC. | $106.48 | 2020-2021 | |
| Dompe US, INC. | $70.66 | 2019-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $61.49 | 2021 | |
| Oyster Point Pharma, INC. | $52.94 | 2024-2025 | Tyrvaya |
| Carl Zeiss Meditec USA, INC. | $36.92 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $24.18 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $23.38 | 2025 | Xdemvy |
| Amgen INC. | $23.19 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.04 | 2019 | |
| Astellas Pharma US INC | $16.23 | 2025 | Izervay |
| Thea Pharma INC. | $15.84 | 2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $15.59 | 2024 | Dextenza |
| Genentech, INC. | $11.09 | 2020 | |
| Abb Con-Cise Optical Group LLC | $6.66 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brock Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.